Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
50 questions in 13 reviews · Childhood Cancer
current versionsNo studies 50 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV) Thromboembolism ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention or placebo Secondary malignant neoplasms · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention Progression‐free survival · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention Quality of life · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention or placebo Quality of life · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation Overall survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents,… (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation Quality‐adjusted survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents,… (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation Toxicity · children, adolescents, and young adults with primary metastatic Ewing sarcoma High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents,… (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents,… (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous platinum infusion vs bolus platinum infusion Tinnitus ‐ not reported · children with cancer treated with platinum‐based therapy Different infusion durations for preventing platinum‐induced hearing loss in children with cancer (2020) · Cochrane | no estimate extracted | NR | No studies |
Continuous platinum infusion vs bolus platinum infusion Overall survival ‐ not reported · children with cancer treated with platinum‐based therapy Different infusion durations for preventing platinum‐induced hearing loss in children with cancer (2020) · Cochrane | no estimate extracted | NR | No studies |
Continuous platinum infusion vs bolus platinum infusion Event‐free survival ‐ not reported · children with cancer treated with platinum‐based therapy Different infusion durations for preventing platinum‐induced hearing loss in children with cancer (2020) · Cochrane | no estimate extracted | NR | No studies |
Continuous platinum infusion vs bolus platinum infusion Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy Different infusion durations for preventing platinum‐induced hearing loss in children with cancer (2020) · Cochrane | no estimate extracted | NR | No studies |
Amifostine vs no otoprotective intervention Quality of life – not reported · children with cancer treated with platinum‐based therapy Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Sodium thiosulfate vs no otoprotective intervention Survival · children with cancer treated with platinum‐based therapy Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Sodium thiosulfate vs no otoprotective intervention Tumour response · children with cancer treated with platinum‐based therapy Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Sodium thiosulfate vs no otoprotective intervention Quality of life · children with cancer treated with platinum‐based therapy Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Sodium thiosulfate vs no otoprotective intervention Quality of life – not reported · children with cancer treated with platinum‐based therapy Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Amifostine vs no otoprotective intervention Survival · children with cancer treated with platinum‐based therapy Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Amifostine vs no otoprotective intervention Survival (overall and event‐free) – not reported · children with cancer treated with platinum‐based therapy Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Amifostine vs no otoprotective intervention Tumour response · children with cancer treated with platinum‐based therapy Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Amifostine vs no otoprotective intervention Quality of life · children with cancer treated with platinum‐based therapy Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Dinutuximab‐containing immunotherapy vs standard therapy Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma… (2019) · Cochrane | no estimate extracted | NR | No studies |
Dinutuximab‐containing immunotherapy vs standard therapy Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma… (2019) · Cochrane | no estimate extracted | NR | No studies |
Dinutuximab‐containing immunotherapy vs standard therapy Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma… (2019) · Cochrane | no estimate extracted | NR | No studies |
Dinutuximab‐containing immunotherapy vs standard therapy Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma… (2019) · Cochrane | no estimate extracted | NR | No studies |
Dinutuximab‐containing immunotherapy vs standard therapy Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma… (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase AUC of serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: urate oxidase vs allopurinol Percentage reduction in serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase Incidence of clinical tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Retinoic acid postconsolidation therapy vs no further treatment Treatment‐related mortality ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous… (2017) · Cochrane | no estimate extracted | NR | No studies |
Retinoic acid postconsolidation therapy vs no further treatment Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous… (2017) · Cochrane | no estimate extracted | NR | No studies |
Retinoic acid postconsolidation therapy vs no further treatment Early toxicity ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous… (2017) · Cochrane | no estimate extracted | NR | No studies |
Retinoic acid postconsolidation therapy vs no further treatment Late toxicity including secondary malignancies ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous… (2017) · Cochrane | no estimate extracted | NR | No studies |
Retinoic acid postconsolidation therapy vs no further treatment Health‐related quality of life ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous… (2017) · Cochrane | no estimate extracted | NR | No studies |
Very early discharge vs early discharge Costs · children with cancer Very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile… (2016) · Cochrane | no estimate extracted | NR | No studies |
Very early discharge vs early discharge Quality of life · children with cancer Very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile… (2016) · Cochrane | no estimate extracted | NR | No studies |
Early discharge vs non‐early discharge Quality of life · children with cancer Very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile… (2016) · Cochrane | no estimate extracted | NR | No studies |
Physical exercise training vs usual care Body composition outcomes · children and young adults during and after treatment for childhood cancer Physical exercise training interventions for children and young adults during and after treatment for… (2016) · Cochrane | no estimate extracted | NR | No studies |
Physical exercise training vs usual care Fatigue · children and young adults during and after treatment for childhood cancer Physical exercise training interventions for children and young adults during and after treatment for… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intracystic bleomycin vs other types of intracystic treatment Survival · cystic craniopharyngiomas in children from birth to 18 years old Intracystic bleomycin for cystic craniopharyngiomas in children (2016) · Cochrane | no estimate extracted | NR | No studies |
Hypofractionated radiotherapy vs conventional radiotherapy Event‐free survival · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane | no estimate extracted | NR | No studies |
Hypofractionated radiotherapy vs conventional radiotherapy Quality of life · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane | no estimate extracted | NR | No studies |
Hypofractionated radiotherapy vs conventional radiotherapy Neurological response · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane | no estimate extracted | NR | No studies |
Hypofractionated radiotherapy vs conventional radiotherapy Radiological response · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane | no estimate extracted | NR | No studies |
Hyperfractionated radiotherapy vs conventional radiotherapy Progression‐free survival · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane | no estimate extracted | NR | No studies |
Hyperfractionated radiotherapy vs conventional radiotherapy Quality of life · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane | no estimate extracted | NR | No studies |
Hyperfractionated radiotherapy vs conventional radiotherapy Neurological response · children and young adults with diffuse brainstem glioma Radiotherapy for diffuse brainstem glioma in children and young adults (2016) · Cochrane | no estimate extracted | NR | No studies |
Rapid COJEC vs standard induction therapies Progression‐free survival ‐ not reported · patients with high‐risk neuroblastoma Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma (2015) · Cochrane | no estimate extracted | NR | No studies |